Evotec's Strategic Overhaul Meets Activist Demands as Shares Rebound

Shares of German biotech firm Evotec have staged a remarkable 35% rally over the past month, a surge that underscores a stark divide between near-term financial pressures and long-term strategic optimism. The stock gained another 3.68% on Tuesday to close at EUR 5.64, steadily climbing from its March low and approaching its 200-day moving average. This upward momentum persists even as the company braces for a loss-making year, highlighting the complex forces currently shaping its future.

Behind the scenes, activist investor MAK Capital is pushing for radical change. The firm, which holds a roughly 7% stake, is publicly urging Evotec to carve out and pursue a separate U.S. listing for its biologics subsidiary, Just – Evotec Biologics. MAK Capital values this unit at over EUR 1 billion. The division is in the spotlight this week, showcasing its new J.Train platform at industry events in New York and Seattle, a technology designed to accelerate the production of biopharmaceuticals.

This external pressure for a spin-off clashes with management’s existing transformation plan, dubbed “Horizon.” That internal strategy aims to consolidate Evotec’s global footprint to ten sites and deliver approximately EUR 75 million in savings by the end of 2027. Spearheading this operational restructuring will be Dr. Ingrid Müller, who assumes the role of Chief Operating Officer on May 1. MAK Capital is demanding faster progress and has called for changes on the company’s supervisory board.

Should investors sell immediately? Or is it worth buying Evotec?

The fundamental picture fueling this strategic tension remains challenging. While Evotec posted a profit in the last quarter on revenue of around EUR 253 million, analysts on average expect a full-year loss per share of EUR 0.46. For the upcoming quarterly report, HC Wainwright analyst S. Ramakanth forecasts a loss of $0.11 per share. Despite this, his firm maintains a Buy rating with a $7 price target, reflecting a longer-term view.

This divergence is mirrored across the analyst community, resulting in an extreme range of valuations. RBC stands as one of the most bullish, assigning a EUR 10 price target and a Buy recommendation, implying a near-doubling of the share price. Berenberg Bank is also positive. In stark contrast, Deutsche Bank rates the stock a Hold with a EUR 4.50 target. The average price target among market watchers sits near EUR 8.

For the current year, Evotec is targeting revenue of up to EUR 780 million but has cautioned that operational improvements are not expected until the second half. Investors are now watching for new partnership announcements, potentially arising from events like the German Biotech Days, which could provide the fundamental support needed to justify the recent share price recovery and navigate the competing visions for the company’s path forward.

Ad

Evotec Stock: New Analysis - 21 April

Fresh Evotec information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Evotec analysis...

en | DE0005664809 | EVOTECS | boerse | 69231642 |